Gilead Sciences Inc
NASDAQ:GILD
Intrinsic Value
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. [ Read More ]
The intrinsic value of one GILD stock under the Base Case scenario is 78.72 USD. Compared to the current market price of 73.25 USD, Gilead Sciences Inc is Undervalued by 7%.
Valuation Backtest
Gilead Sciences Inc
Run backtest to discover the historical profit from buying and selling GILD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Gilead's Strong HIV Market Dominance
2023-Q4 Earnings Call
Gilead Sciences revealed that despite a 2% year-over-year decline in sales due to lower prices from channel mix changes, sequential sales grew by 1%. In 2024, they predict a 4% growth in HIV sales, banking on treatment demand and HIV prevention. The first quarter tends to see a 10-12% decline due to inventory adjustments. Their HIV treatments, especially Biktarvy, continue strong performance, maintaining a dominant market share (over 70% in the U.S.). Liver disease sales were stable at $2.8 billion yearly. However, the oncology business excelled with a 24% year-over-year increase, exceeding $3 billion in annualized revenue, propelled by Trodelvy's success. The cell therapy sector approached $2 billion in 2023 with Kite leading the CAR T-cell therapy market globally. Despite some disappointments in clinical trials, such as EVOKE-01 not meeting its primary endpoint, Gilead's commitment to innovation persists.
Balance Sheet Decomposition
Gilead Sciences Inc
Current Assets | 16.1B |
Cash & Short-Term Investments | 9.6B |
Receivables | 4.7B |
Other Current Assets | 1.8B |
Non-Current Assets | 46B |
Long-Term Investments | 1.2B |
PP&E | 5.3B |
Intangibles | 34.8B |
Other Non-Current Assets | 4.8B |
Current Liabilities | 11.3B |
Accounts Payable | 550m |
Accrued Liabilities | 7.7B |
Other Current Liabilities | 3B |
Non-Current Liabilities | 28B |
Long-Term Debt | 23.2B |
Other Non-Current Liabilities | 4.8B |
Earnings Waterfall
Gilead Sciences Inc
Revenue
|
27.1B
USD
|
Cost of Revenue
|
-6B
USD
|
Gross Profit
|
21.1B
USD
|
Operating Expenses
|
-12.9B
USD
|
Operating Income
|
8.2B
USD
|
Other Expenses
|
-2.5B
USD
|
Net Income
|
5.7B
USD
|
Free Cash Flow Analysis
Gilead Sciences Inc
What is Free Cash Flow?
GILD Profitability Score
Profitability Due Diligence
Gilead Sciences Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Gilead Sciences Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
GILD Solvency Score
Solvency Due Diligence
Gilead Sciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Gilead Sciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GILD Price Targets Summary
Gilead Sciences Inc
According to Wall Street analysts, the average 1-year price target for GILD is 87.56 USD with a low forecast of 69.69 USD and a high forecast of 127.05 USD.
Ownership
GILD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GILD Price
Gilead Sciences Inc
Average Annual Return | 12.01% |
Standard Deviation of Annual Returns | 14.74% |
Max Drawdown | -30% |
Market Capitalization | 91.3B USD |
Shares Outstanding | 1 245 770 000 |
Percentage of Shares Shorted | 1.77% |
GILD News
Last Important Events
Gilead Sciences Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Gilead Sciences Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 14,400 full-time employees. The firm is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The firm also sells and distributes generic versions of Epclusa and Harvoni in the United States. The company sells and distributes its products in the United States through the wholesale channel. The company operates in more than 35 countries worldwide.
Contact
IPO
Employees
Officers
The intrinsic value of one GILD stock under the Base Case scenario is 78.72 USD.
Compared to the current market price of 73.25 USD, Gilead Sciences Inc is Undervalued by 7%.